Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 125

1.

Drug repositioning for Alzheimer's disease.

Corbett A, Pickett J, Burns A, Corcoran J, Dunnett SB, Edison P, Hagan JJ, Holmes C, Jones E, Katona C, Kearns I, Kehoe P, Mudher A, Passmore A, Shepherd N, Walsh F, Ballard C.

Nat Rev Drug Discov. 2012 Nov;11(11):833-46. doi: 10.1038/nrd3869. Review.

PMID:
23123941
2.

Enhanced appetitive learning and reversal learning in a mouse model for Prader-Willi syndrome.

Relkovic D, Humby T, Hagan JJ, Wilkinson LS, Isles AR.

Behav Neurosci. 2012 Jun;126(3):488-92. doi: 10.1037/a0028155.

PMID:
22642890
3.

Short-term individual housing induced social deficits in female Mongolian gerbils: attenuation by chronic but not acute imipramine.

Pickles AR, Hagan JJ, Jones DN, Hendrie CA.

Neuropharmacology. 2012 Apr;62(5-6):1993-8. doi: 10.1016/j.neuropharm.2011.12.016. Epub 2012 Jan 5.

PMID:
22244943
4.

Transcription and pathway analysis of the superior temporal cortex and anterior prefrontal cortex in schizophrenia.

Barnes MR, Huxley-Jones J, Maycox PR, Lennon M, Thornber A, Kelly F, Bates S, Taylor A, Reid J, Jones N, Schroeder J, Scorer CA, Davies C, Hagan JJ, Kew JN, Angelinetta C, Akbar T, Hirsch S, Mortimer AM, Barnes TR, de Belleroche J.

J Neurosci Res. 2011 Aug;89(8):1218-27. doi: 10.1002/jnr.22647. Epub 2011 Apr 27.

PMID:
21538462
5.

N-desmethylclozapine (NDMC) is an antagonist at the human native muscarinic M(1) receptor.

Thomas DR, Dada A, Jones GA, Deisz RA, Gigout S, Langmead CJ, Werry TD, Hendry N, Hagan JJ, Davies CH, Watson JM.

Neuropharmacology. 2010 Jun;58(8):1206-14. doi: 10.1016/j.neuropharm.2010.02.017. Epub 2010 Mar 3.

PMID:
20206188
6.

Behavioural and cognitive abnormalities in an imprinting centre deletion mouse model for Prader-Willi syndrome.

Relkovic D, Doe CM, Humby T, Johnstone KA, Resnick JL, Holland AJ, Hagan JJ, Wilkinson LS, Isles AR.

Eur J Neurosci. 2010 Jan;31(1):156-64. doi: 10.1111/j.1460-9568.2009.07048.x. Epub 2009 Dec 23.

PMID:
20092561
7.

New opportunities for the management and therapy of hepatitis C in correctional settings.

Martin CK, Hostetter JE, Hagan JJ.

Am J Public Health. 2010 Jan;100(1):13-7. doi: 10.2105/AJPH.2008.147629.

8.

In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics.

Dawson LA, Langmead CJ, Dada A, Watson JM, Wu Z, de la Flor R, Jones GA, Cluderay JE, Southam E, Murkitt GS, Hill MD, Jones DN, Davies CH, Hagan JJ, Smith PW.

Eur J Pharmacol. 2010 Feb 10;627(1-3):106-14. doi: 10.1016/j.ejphar.2009.10.054. Epub 2009 Oct 30.

PMID:
19879867
9.

Chronic fluoxetine differentially modulates the hippocampal microtubular and serotonergic system in grouped and isolation reared rats.

Bianchi M, Fone KC, Shah AJ, Atkins AR, Dawson LA, Heidbreder CA, Hagan JJ, Marsden CA.

Eur Neuropsychopharmacol. 2009 Nov;19(11):778-90. doi: 10.1016/j.euroneuro.2009.06.005. Epub 2009 Jul 7.

PMID:
19584022
10.

Altered M(1) muscarinic acetylcholine receptor (CHRM1)-Galpha(q/11) coupling in a schizophrenia endophenotype.

Salah-Uddin H, Scarr E, Pavey G, Harris K, Hagan JJ, Dean B, Challiss RA, Watson JM.

Neuropsychopharmacology. 2009 Aug;34(9):2156-66. doi: 10.1038/npp.2009.41. Epub 2009 Apr 29.

11.

Analysis of gene expression in two large schizophrenia cohorts identifies multiple changes associated with nerve terminal function.

Maycox PR, Kelly F, Taylor A, Bates S, Reid J, Logendra R, Barnes MR, Larminie C, Jones N, Lennon M, Davies C, Hagan JJ, Scorer CA, Angelinetta C, Akbar MT, Hirsch S, Mortimer AM, Barnes TR, de Belleroche J.

Mol Psychiatry. 2009 Dec;14(12):1083-94. doi: 10.1038/mp.2009.18. Epub 2009 Mar 3. Erratum in: Mol Psychiatry. 2009 Dec;14(12):1146. Akbar, T [corrected to Akbar, M T]. Mol Psychiatry. 2010 Apr;15(4):442-3.

12.

Fluoxetine administration modulates the cytoskeletal microtubular system in the rat hippocampus.

Bianchi M, Shah AJ, Fone KC, Atkins AR, Dawson LA, Heidbreder CA, Hows ME, Hagan JJ, Marsden CA.

Synapse. 2009 Apr;63(4):359-64. doi: 10.1002/syn.20614.

PMID:
19140168
13.

The selective 5-HT6 receptor antagonists SB-271046 and SB-399885 potentiate NCAM PSA immunolabeling of dentate granule cells, but not neurogenesis, in the hippocampal formation of mature Wistar rats.

Foley AG, Hirst WD, Gallagher HC, Barry C, Hagan JJ, Upton N, Walsh FS, Hunter AJ, Regan CM.

Neuropharmacology. 2008 Jun;54(8):1166-74. doi: 10.1016/j.neuropharm.2008.03.012. Epub 2008 Apr 1.

PMID:
18455201
14.

Characterization of a CNS penetrant, selective M1 muscarinic receptor agonist, 77-LH-28-1.

Langmead CJ, Austin NE, Branch CL, Brown JT, Buchanan KA, Davies CH, Forbes IT, Fry VA, Hagan JJ, Herdon HJ, Jones GA, Jeggo R, Kew JN, Mazzali A, Melarange R, Patel N, Pardoe J, Randall AD, Roberts C, Roopun A, Starr KR, Teriakidis A, Wood MD, Whittington M, Wu Z, Watson J.

Br J Pharmacol. 2008 Jul;154(5):1104-15. doi: 10.1038/bjp.2008.152. Epub 2008 May 5.

15.

Pharmacological assessment of m1 muscarinic acetylcholine receptor-gq/11 protein coupling in membranes prepared from postmortem human brain tissue.

Salah-Uddin H, Thomas DR, Davies CH, Hagan JJ, Wood MD, Watson JM, Challiss RA.

J Pharmacol Exp Ther. 2008 Jun;325(3):869-74. doi: 10.1124/jpet.108.137968. Epub 2008 Mar 5.

PMID:
18322150
16.

1,2,4-triazol-3-yl-thiopropyl-tetrahydrobenzazepines: a series of potent and selective dopamine D(3) receptor antagonists.

Micheli F, Bonanomi G, Blaney FE, Braggio S, Capelli AM, Checchia A, Curcuruto O, Damiani F, Fabio RD, Donati D, Gentile G, Gribble A, Hamprecht D, Tedesco G, Terreni S, Tarsi L, Lightfoot A, Stemp G, Macdonald G, Smith A, Pecoraro M, Petrone M, Perini O, Piner J, Rossi T, Worby A, Pilla M, Valerio E, Griffante C, Mugnaini M, Wood M, Scott C, Andreoli M, Lacroix L, Schwarz A, Gozzi A, Bifone A, Ashby CR Jr, Hagan JJ, Heidbreder C.

J Med Chem. 2007 Oct 18;50(21):5076-89. Epub 2007 Sep 15.

PMID:
17867665
17.

Dopamine D2 receptor stimulation inhibits cold-initiated thermogenesis in brown adipose tissue in conscious rats.

Ootsuka Y, Heidbreder CA, Hagan JJ, Blessing WW.

Neuroscience. 2007 Jun 15;147(1):127-35. Epub 2007 May 21.

PMID:
17512675
18.

SB-649915-B, a novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test.

Starr KR, Price GW, Watson JM, Atkinson PJ, Arban R, Melotto S, Dawson LA, Hagan JJ, Upton N, Duxon MS.

Neuropsychopharmacology. 2007 Oct;32(10):2163-72. Epub 2007 Mar 14.

19.
20.

Isolation rearing induces recognition memory deficits accompanied by cytoskeletal alterations in rat hippocampus.

Bianchi M, Fone KF, Azmi N, Heidbreder CA, Hagan JJ, Marsden CA.

Eur J Neurosci. 2006 Nov;24(10):2894-902. Epub 2006 Nov 20.

PMID:
17116162
21.

Studies towards the identification of a new generation of atypical antipsychotic agents.

Garzya V, Forbes IT, Gribble AD, Hadley MS, Lightfoot AP, Payne AH, Smith AB, Douglas SE, Cooper DG, Stansfield IG, Meeson M, Dodds EE, Jones DN, Wood M, Reavill C, Scorer CA, Worby A, Riley G, Eddershaw P, Ioannou C, Donati D, Hagan JJ, Ratti EA.

Bioorg Med Chem Lett. 2007 Jan 15;17(2):400-5. Epub 2006 Oct 19.

PMID:
17084080
22.

SB-699551-A (3-cyclopentyl-N-[2-(dimethylamino)ethyl]-N-[(4'-{[(2-phenylethyl)amino]methyl}-4-biphenylyl)methyl]propanamide dihydrochloride), a novel 5-ht5A receptor-selective antagonist, enhances 5-HT neuronal function: Evidence for an autoreceptor role for the 5-ht5A receptor in guinea pig brain.

Thomas DR, Soffin EM, Roberts C, Kew JN, de la Flor RM, Dawson LA, Fry VA, Coggon SA, Faedo S, Hayes PD, Corbett DF, Davies CH, Hagan JJ.

Neuropharmacology. 2006 Sep;51(3):566-77. Epub 2006 Jul 17.

PMID:
16846620
23.

Long-lasting changes in behavioural and neuroendocrine indices in the rat following neonatal maternal separation: gender-dependent effects.

Slotten HA, Kalinichev M, Hagan JJ, Marsden CA, Fone KC.

Brain Res. 2006 Jun 30;1097(1):123-32. Epub 2006 May 30.

PMID:
16730678
25.

SB-649915, a novel, potent 5-HT1A and 5-HT1B autoreceptor antagonist and 5-HT re-uptake inhibitor in native tissue.

Scott C, Soffin EM, Hill M, Atkinson PJ, Langmead CJ, Wren PB, Faedo S, Gordon LJ, Price GW, Bromidge S, Johnson CN, Hagan JJ, Watson J.

Eur J Pharmacol. 2006 Apr 24;536(1-2):54-61. Epub 2006 Feb 28.

PMID:
16571351
26.

SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1-[2'methyl-4'-(5-methyl-1,2,3-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): a novel, potent and selective 5-HT1B receptor antagonist.

Scott C, Langmead CJ, Clarke KL, Wyman P, Smith PW, Starr KR, Dawson LA, Price GW, Hagan JJ, Watson J.

Neuropharmacology. 2006 Jun;50(8):984-90. Epub 2006 Mar 20.

PMID:
16546225
27.

Neuronal plasticity, stress and depression: involvement of the cytoskeletal microtubular system?

Bianchi M, Hagan JJ, Heidbreder CA.

Curr Drug Targets CNS Neurol Disord. 2005 Oct;4(5):597-611. Review.

PMID:
16266292
28.

Predicting drug efficacy for cognitive deficits in schizophrenia.

Hagan JJ, Jones DN.

Schizophr Bull. 2005 Oct;31(4):830-53. Epub 2005 Sep 21. Review.

PMID:
16177277
29.

Effect of vilazodone on 5-HT efflux and re-uptake in the guinea-pig dorsal raphe nucleus.

Roberts C, Hagan JJ, Bartoszyk GD, Kew JN.

Eur J Pharmacol. 2005 Jul 4;517(1-2):59-63.

PMID:
15978574
30.

The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence.

Heidbreder CA, Gardner EL, Xi ZX, Thanos PK, Mugnaini M, Hagan JJ, Ashby CR Jr.

Brain Res Brain Res Rev. 2005 Jul;49(1):77-105. Review.

31.

5-HT6 receptor antagonists improve performance in an attentional set shifting task in rats.

Hatcher PD, Brown VJ, Tait DS, Bate S, Overend P, Hagan JJ, Jones DN.

Psychopharmacology (Berl). 2005 Sep;181(2):253-9. Epub 2005 Oct 14.

PMID:
15846482
32.

Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.

Hughes ZA, Starr KR, Langmead CJ, Hill M, Bartoszyk GD, Hagan JJ, Middlemiss DN, Dawson LA.

Eur J Pharmacol. 2005 Mar 7;510(1-2):49-57.

PMID:
15740724
33.

Novel pharmacotherapeutic approaches for the treatment of drug addiction and craving.

Heidbreder CA, Hagan JJ.

Curr Opin Pharmacol. 2005 Feb;5(1):107-18. Review.

PMID:
15661634
34.

Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets.

Jackson MJ, Al-Barghouthy G, Pearce RK, Smith L, Hagan JJ, Jenner P.

Pharmacol Biochem Behav. 2004 Nov;79(3):391-400.

PMID:
15582011
35.

Localisation of NMU1R and NMU2R in human and rat central nervous system and effects of neuromedin-U following central administration in rats.

Gartlon J, Szekeres P, Pullen M, Sarau HM, Aiyar N, Shabon U, Michalovich D, Steplewski K, Ellis C, Elshourbagy N, Duxon M, Ashmeade TE, Harrison DC, Murdock P, Wilson S, Ennaceur A, Atkins A, Heidbreder C, Hagan JJ, Hunter AJ, Jones DN.

Psychopharmacology (Berl). 2004 Dec;177(1-2):1-14. Epub 2004 Jun 16.

PMID:
15205870
36.

Urotensin-II, a neuropeptide ligand for GPR14, induces c-fos in the rat brain.

Gartlon JE, Ashmeade T, Duxon M, Hagan JJ, Jones DN.

Eur J Pharmacol. 2004 Jun 16;493(1-3):95-8.

PMID:
15189768
37.

5-HT7 receptor subtype as a mediator of the serotonergic regulation of luteinizing hormone release in the zona incerta.

Siddiqui A, Abu-Amara M, Aldairy C, Hagan JJ, Wilson C.

Eur J Pharmacol. 2004 Apr 26;491(1):77-84.

PMID:
15102536
38.

Blockade of mesolimbic dopamine D3 receptors inhibits stress-induced reinstatement of cocaine-seeking in rats.

Xi ZX, Gilbert J, Campos AC, Kline N, Ashby CR Jr, Hagan JJ, Heidbreder CA, Gardner EL.

Psychopharmacology (Berl). 2004 Oct;176(1):57-65. Epub 2004 Apr 9.

39.

5-HT7 receptors.

Thomas DR, Hagan JJ.

Curr Drug Targets CNS Neurol Disord. 2004 Feb;3(1):81-90. Review.

PMID:
14965246
40.
41.

5-HT6 receptor antagonist SB-271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex.

Lacroix LP, Dawson LA, Hagan JJ, Heidbreder CA.

Synapse. 2004 Feb;51(2):158-64.

PMID:
14618683
42.

Design and synthesis of trans-3-(2-(4-((3-(3-(5-methyl-1,2,4-oxadiazolyl))- phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro-1H-3-benzazepine (SB-414796): a potent and selective dopamine D3 receptor antagonist.

Macdonald GJ, Branch CL, Hadley MS, Johnson CN, Nash DJ, Smith AB, Stemp G, Thewlis KM, Vong AK, Austin NE, Jeffrey P, Winborn KY, Boyfield I, Hagan JJ, Middlemiss DN, Reavill C, Riley GJ, Watson JM, Wood M, Parker SG, Ashby CR Jr.

J Med Chem. 2003 Nov 6;46(23):4952-64.

PMID:
14584946
43.

The 5-HT(6) receptor antagonist SB-271046 reverses scopolamine-disrupted consolidation of a passive avoidance task and ameliorates spatial task deficits in aged rats.

Foley AG, Murphy KJ, Hirst WD, Gallagher HC, Hagan JJ, Upton N, Walsh FS, Regan CM.

Neuropsychopharmacology. 2004 Jan;29(1):93-100.

44.

Effects of fluoxetine on social behaviour and plasma corticosteroid levels in female Mongolian gerbils.

Hendrie CA, Pickles AR, Duxon MS, Riley G, Hagan JJ.

Behav Pharmacol. 2003 Nov;14(7):545-50.

PMID:
14557722
45.

SB-656104-A, a novel selective 5-HT7 receptor antagonist, modulates REM sleep in rats.

Thomas DR, Melotto S, Massagrande M, Gribble AD, Jeffrey P, Stevens AJ, Deeks NJ, Eddershaw PJ, Fenwick SH, Riley G, Stean T, Scott CM, Hill MJ, Middlemiss DN, Hagan JJ, Price GW, Forbes IT.

Br J Pharmacol. 2003 Jun;139(4):705-14.

46.

Selective antagonism at dopamine D3 receptors prevents nicotine-triggered relapse to nicotine-seeking behavior.

Andreoli M, Tessari M, Pilla M, Valerio E, Hagan JJ, Heidbreder CA.

Neuropsychopharmacology. 2003 Jul;28(7):1272-80. Epub 2003 Apr 16.

47.
48.

Selective antagonism at dopamine D3 receptors enhances monoaminergic and cholinergic neurotransmission in the rat anterior cingulate cortex.

Lacroix LP, Hows ME, Shah AJ, Hagan JJ, Heidbreder CA.

Neuropsychopharmacology. 2003 May;28(5):839-49. Epub 2003 Mar 12.

49.

Attenuation of cue-controlled cocaine-seeking by a selective D3 dopamine receptor antagonist SB-277011-A.

Di Ciano P, Underwood RJ, Hagan JJ, Everitt BJ.

Neuropsychopharmacology. 2003 Feb;28(2):329-38. Epub 2002 Jun 18.

50.

Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats.

Vorel SR, Ashby CR Jr, Paul M, Liu X, Hayes R, Hagan JJ, Middlemiss DN, Stemp G, Gardner EL.

J Neurosci. 2002 Nov 1;22(21):9595-603.

Supplemental Content

Loading ...
Support Center